RAND researchers conducted a systematic review that synthesized evidence from randomized controlled trials of Mindfulness-Based Relapse Prevention (MBRP) — used as an adjunctive therapy or monotherapy — to provide estimates of its efficacy and safety for treating adults diagnosed with alcohol, opioid, stimulant, or cannabis use disorder.